These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Janjua S; Fortescue R; Poole P Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609 [TBL] [Abstract][Full Text] [Related]
44. Interventions for bacterial folliculitis and boils (furuncles and carbuncles). Lin HS; Lin PT; Tsai YS; Wang SH; Chi CC Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013099. PubMed ID: 33634465 [TBL] [Abstract][Full Text] [Related]
51. Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds. Gurusamy KS; Koti R; Toon CD; Wilson P; Davidson BR Cochrane Database Syst Rev; 2013 Nov; (11):CD010427. PubMed ID: 24242704 [TBL] [Abstract][Full Text] [Related]
52. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Aslam AA; Higgins C; Sinha IP; Southern KW Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012040. PubMed ID: 28102546 [TBL] [Abstract][Full Text] [Related]
53. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Aslam AA; Sinha IP; Southern KW Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921 [TBL] [Abstract][Full Text] [Related]
54. Interventions to reduce Staphylococcus aureus in the management of eczema. George SM; Karanovic S; Harrison DA; Rani A; Birnie AJ; Bath-Hextall FJ; Ravenscroft JC; Williams HC Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684694 [TBL] [Abstract][Full Text] [Related]
55. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Southern KW; Murphy J; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662 [TBL] [Abstract][Full Text] [Related]
56. Digital technology for early identification of exacerbations in people with cystic fibrosis. Wong CH; Smith S; Kansra S Cochrane Database Syst Rev; 2023 Apr; 4(4):CD014606. PubMed ID: 37057835 [TBL] [Abstract][Full Text] [Related]
57. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
58. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]